Sino Biopharmaceutical Limited (SBMFF.PK), Tuesday announced the completion of the first subject enrollment and successful dosing in a Phase I clinical study of TQB6411 for injection.
The phase 1 clinical study deals with evaluation of safety, tolerability, pharmacokinetics and preliminary efficacy of TQB6411 in humans.
Preclinical in vivo pharmacodynamic studies have demonstrated a clear anti-tumor mechanism of action, showing anti-tumor activity in animal models with varying expression levels and resistance profiles of EGFR and c-Met.
In addition to TQB6411 , the company is working on several ADC projects, which are expected to enter clinical stages progressively over the next 1-2 years.
Sunday, Sino's stock closed at $0.8760, down 4.37 percent on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.